Literature DB >> 10741715

Immunoprotective activities of multiple chaperone proteins isolated from murine B-cell leukemia/lymphoma.

M Graner1, A Raymond, D Romney, L He, L Whitesell, E Katsanis.   

Abstract

Although the use of tumor-derived heat shock/chaperone proteins (HSPs) as anticancer vaccines is gaining wider study and acceptance, there have thus far been no reports concerning chaperone antitumor activities against disseminated hematological malignancies. We have devised an efficient and effective method for purification of the chaperone proteins grp94/gp96, HSP90, HSP70, and calreticulin from harvested A20 murine leukemia/lymphoma tumor material. We have demonstrated that these purified proteins, when used as vaccines, can induce potent and specific immunity against a lethal tumor challenge. Individual chaperone proteins were differentially effective in their abilities to provide immune protection. The increase in survival generated by the most effective chaperone vaccine, HSP70, resulted from at least a 2-log reduction in tumor burden. Syngeneic granulocyte macrophage colony-stimulating factor producing fibroblasts were injected at the site of vaccination in an attempt to augment the immune response. Surprisingly, localized granulocyte macrophage colony-stimulating factor production inhibited the protective effects of chaperone vaccination. These studies provide evidence that chaperone proteins can be isolated from B-cell tumors and used effectively to immunize against disseminated lymphoid malignancies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741715

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  21 in total

1.  Co-expression of heat shock protein 70 and glucose-regulated protein 94 in human gastric carcinoma cell line BGC-823.

Authors:  Xiao-Ping Wang; Jing Liao; Guo-Zhen Liu; Xing-Cui Wang; Hong-Wei Shang
Journal:  World J Gastroenterol       Date:  2005-06-21       Impact factor: 5.742

2.  Signaling pathways induced by a tumor-derived vaccine in antigen presenting cells.

Authors:  Jessica Cantrell; Claire Larmonier; Nona Janikashvili; Sara Bustamante; Jennifer Fraszczak; Amanda Herrell; Tamara Lundeen; Collin J LaCasse; Elaine Situ; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Immunobiology       Date:  2009-10-31       Impact factor: 3.144

3.  Creation of Recombinant Chaperone Vaccine Using Large Heat Shock Protein for Antigen-Targeted Cancer Immunotherapy.

Authors:  Chunqing Guo; John R Subjeck; Xiang-Yang Wang
Journal:  Methods Mol Biol       Date:  2018

4.  Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice.

Authors:  Ning Bu; Haiqin Wu; Guilian Zhang; Shuqin Zhan; Ru Zhang; Hong Sun; Yun Du; Li Yao; Huqing Wang
Journal:  J Mol Neurosci       Date:  2015-02-14       Impact factor: 3.444

5.  Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.

Authors:  Nona Janikashvili; Collin J LaCasse; Claire Larmonier; Malika Trad; Amanda Herrell; Sara Bustamante; Bernard Bonnotte; Michael Har-Noy; Nicolas Larmonier; Emmanuel Katsanis
Journal:  Blood       Date:  2010-12-01       Impact factor: 22.113

Review 6.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  High molecular weight stress proteins: Identification, cloning and utilisation in cancer immunotherapy.

Authors:  Xiang-Yang Wang; John R Subjeck
Journal:  Int J Hyperthermia       Date:  2013-07-05       Impact factor: 3.914

8.  Expression and significance of heat shock protein 70 and glucose-regulated protein 94 in human esophageal carcinoma.

Authors:  Xiao-Ping Wang; Guo-Zhen Liu; Ai-Li Song; Rui-Fen Chen; Hai-Yan Li; Yu Liu
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

Review 9.  Facets of heat shock protein 70 show immunotherapeutic potential.

Authors:  Stephen M Todryk; Michael J Gough; A Graham Pockley
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

10.  Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.

Authors:  Yi Zeng; Michael W Graner; Sylvia Thompson; Marilyn Marron; Emmanuel Katsanis
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.